{
    "info": {
        "nct_id": "NCT05169489",
        "official_title": "A Phase 1/2 Study of bbT369, a Dual Targeting CAR T Cell Drug Product With a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)",
        "inclusion_criteria": "* ≥18 years of age at the time of signing informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n* Diagnosis of B-cell NHL according to WHO 2017 classification or WHO 2016 classification where applicable:\n\n  1. DLBCL (germinal center B cell [GCB] or activated B cell [ABC] type or not otherwise specified [NOS])\n  2. HGBCL (with MYC and BCL2 and/or BCL6 rearrangements or NOS)\n  3. PMBCL\n  4. FL 3b\n  5. DLBCL transformed from FL\n* Participants must have relapsed or refractory (r/r) B cell NHL after autologous stem cell transplant (ASCT) or at least 2 prior lines of therapy including an anti-CD20 monoclonal antibody and an anthracycline containing chemotherapy regimen. Note: participants with DLBCL transformed from FL must have r/r disease after ASCT or at least 2 prior therapies following transformation irrespective of therapeutic agents.\n* At least 1 FDG-avid lesion per Lugano Classification criteria at time of enrollment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Treatment with any investigational cellular therapy prior to enrollment. Treatment with an approved anti-CD19 CAR T cell therapy in an investigational setting may be permitted after discussion with and approval of the Sponsor.\n* Progression within 6 weeks of prior anti-CD19 CAR T cell therapy.\n* Residual toxicities or end-organ damage to vital organs from prior therapy that could put a subject at undue risk based on Investigator's assessment. Toxicities related to prior cytokine release syndrome (CRS) or neurotoxicity must be resolved.\n* If a subject has received prior anti-CD19 CAR T therapy, development of ≥ Grade 3 CAR T related CRS or ≥ Grade 3 neurotoxicity that in the opinion of the Investigator would cause unacceptable risk of toxicity to the subject upon treatment with bbT369.\n* Primary central nervous system (CNS) lymphoma or a history or presence of clinically relevant CNS pathology.\n* Active autoimmune disease requiring systemic immunosuppressive and/or cytotoxic therapy within the past two years.\n* Treatment with any prior anti-CD79a therapy.\n* Previous history of an allogeneic bone marrow transplantation. Autologous stem cell transplantation (ASCT) is permitted.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥18 years of age at the time of signing informed consent.",
            "criterions": [
                {
                    "exact_snippets": "≥18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. DLBCL (germinal center B cell [GCB] or activated B cell [ABC] type or not otherwise specified [NOS])",
            "criterions": [
                {
                    "exact_snippets": "DLBCL (germinal center B cell [GCB] or activated B cell [ABC] type or not otherwise specified [NOS])",
                    "criterion": "DLBCL subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "germinal center B cell (GCB)",
                                "activated B cell (ABC)",
                                "not otherwise specified (NOS)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of B-cell NHL according to WHO 2017 classification or WHO 2016 classification where applicable:",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of B-cell NHL according to WHO 2017 classification",
                    "criterion": "B-cell non-Hodgkin lymphoma (NHL) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "B-cell NHL"
                        },
                        {
                            "requirement_type": "classification_system",
                            "expected_value": "WHO 2017"
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of B-cell NHL ... or WHO 2016 classification where applicable",
                    "criterion": "B-cell non-Hodgkin lymphoma (NHL) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "B-cell NHL"
                        },
                        {
                            "requirement_type": "classification_system",
                            "expected_value": "WHO 2016"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. HGBCL (with MYC and BCL2 and/or BCL6 rearrangements or NOS)",
            "criterions": [
                {
                    "exact_snippets": "HGBCL (with MYC and BCL2 and/or BCL6 rearrangements or NOS)",
                    "criterion": "HGBCL",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with MYC and BCL2 and/or BCL6 rearrangements",
                    "criterion": "MYC rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with MYC and BCL2 and/or BCL6 rearrangements",
                    "criterion": "BCL2 rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with MYC and BCL2 and/or BCL6 rearrangements",
                    "criterion": "BCL6 rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "or NOS",
                    "criterion": "NOS (Not Otherwise Specified) HGBCL",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. PMBCL",
            "criterions": [
                {
                    "exact_snippets": "PMBCL",
                    "criterion": "PMBCL (Primary Mediastinal B-cell Lymphoma)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. FL 3b",
            "criterions": [
                {
                    "exact_snippets": "FL 3b",
                    "criterion": "follicular lymphoma grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "3b"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. DLBCL transformed from FL",
            "criterions": [
                {
                    "exact_snippets": "DLBCL transformed from FL",
                    "criterion": "DLBCL transformation from FL",
                    "requirements": [
                        {
                            "requirement_type": "transformation",
                            "expected_value": "DLBCL transformed from FL"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 1 FDG-avid lesion per Lugano Classification criteria at time of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "At least 1 FDG-avid lesion per Lugano Classification criteria at time of enrollment.",
                    "criterion": "FDG-avid lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "FDG-avidity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at time of enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have relapsed or refractory (r/r) B cell NHL after autologous stem cell transplant (ASCT) or at least 2 prior lines of therapy including an anti-CD20 monoclonal antibody and an anthracycline containing chemotherapy regimen. Note: participants with DLBCL transformed from FL must have r/r disease after ASCT or at least 2 prior therapies following transformation irrespective of therapeutic agents.",
            "criterions": [
                {
                    "exact_snippets": "Participants must have relapsed or refractory (r/r) B cell NHL",
                    "criterion": "B cell non-Hodgkin lymphoma (NHL)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "after autologous stem cell transplant (ASCT) or at least 2 prior lines of therapy including an anti-CD20 monoclonal antibody and an anthracycline containing chemotherapy regimen",
                    "criterion": "prior therapy for B cell NHL",
                    "requirements": [
                        {
                            "requirement_type": "prior ASCT",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior lines of therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "prior anti-CD20 monoclonal antibody",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior anthracycline containing chemotherapy regimen",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participants with DLBCL transformed from FL must have r/r disease after ASCT or at least 2 prior therapies following transformation irrespective of therapeutic agents",
                    "criterion": "DLBCL transformed from FL",
                    "requirements": [
                        {
                            "requirement_type": "disease status after transformation",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        },
                        {
                            "requirement_type": "prior ASCT after transformation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior therapies after transformation",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "therapies"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Primary central nervous system (CNS) lymphoma or a history or presence of clinically relevant CNS pathology.",
            "criterions": [
                {
                    "exact_snippets": "Primary central nervous system (CNS) lymphoma",
                    "criterion": "primary central nervous system (CNS) lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history or presence of clinically relevant CNS pathology",
                    "criterion": "clinically relevant CNS pathology",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any investigational cellular therapy prior to enrollment. Treatment with an approved anti-CD19 CAR T cell therapy in an investigational setting may be permitted after discussion with and approval of the Sponsor.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any investigational cellular therapy prior to enrollment.",
                    "criterion": "investigational cellular therapy treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with an approved anti-CD19 CAR T cell therapy in an investigational setting may be permitted after discussion with and approval of the Sponsor.",
                    "criterion": "approved anti-CD19 CAR T cell therapy in an investigational setting",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sponsor approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous history of an allogeneic bone marrow transplantation. Autologous stem cell transplantation (ASCT) is permitted.",
            "criterions": [
                {
                    "exact_snippets": "Previous history of an allogeneic bone marrow transplantation",
                    "criterion": "allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Autologous stem cell transplantation (ASCT) is permitted",
                    "criterion": "autologous stem cell transplantation (ASCT)",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease requiring systemic immunosuppressive and/or cytotoxic therapy within the past two years.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease requiring systemic immunosuppressive and/or cytotoxic therapy within the past two years.",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "systemic immunosuppressive therapy",
                                "cytotoxic therapy"
                            ]
                        },
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progression within 6 weeks of prior anti-CD19 CAR T cell therapy.",
            "criterions": [
                {
                    "exact_snippets": "Progression within 6 weeks of prior anti-CD19 CAR T cell therapy.",
                    "criterion": "disease progression after anti-CD19 CAR T cell therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since prior therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "prior therapy type",
                            "expected_value": "anti-CD19 CAR T cell therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any prior anti-CD79a therapy.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any prior anti-CD79a therapy",
                    "criterion": "prior anti-CD79a therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Residual toxicities or end-organ damage to vital organs from prior therapy that could put a subject at undue risk based on Investigator's assessment. Toxicities related to prior cytokine release syndrome (CRS) or neurotoxicity must be resolved.",
            "criterions": [
                {
                    "exact_snippets": "Residual toxicities or end-organ damage to vital organs from prior therapy that could put a subject at undue risk based on Investigator's assessment.",
                    "criterion": "residual toxicities or end-organ damage to vital organs from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Toxicities related to prior cytokine release syndrome (CRS) or neurotoxicity must be resolved.",
                    "criterion": "toxicities related to prior cytokine release syndrome (CRS) or neurotoxicity",
                    "requirements": [
                        {
                            "requirement_type": "resolution",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* If a subject has received prior anti-CD19 CAR T therapy, development of ≥ Grade 3 CAR T related CRS or ≥ Grade 3 neurotoxicity that in the opinion of the Investigator would cause unacceptable risk of toxicity to the subject upon treatment with bbT369.",
            "criterions": [
                {
                    "exact_snippets": "received prior anti-CD19 CAR T therapy",
                    "criterion": "prior anti-CD19 CAR T therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "development of ≥ Grade 3 CAR T related CRS",
                    "criterion": "CAR T related CRS",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "development of ≥ Grade 3 neurotoxicity",
                    "criterion": "CAR T related neurotoxicity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the Investigator would cause unacceptable risk of toxicity to the subject upon treatment with bbT369",
                    "criterion": "risk of toxicity upon treatment with bbT369",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion of risk",
                            "expected_value": "unacceptable"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}